We are live on ! Find out more
Jeff Yass

Jeff Yass Susquehanna International Group

AUM $1.28T Turnover 24.66%
1-Year Est. Return 58.89%
 

Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.

This Fund
S&P 500
This Quarter Est. Return
+35.7%
1 Year Est. Return
+58.89%
3 Year Est. Return
+161.44%
5 Year Est. Return
+153.95%
10 Year Est. Return
+545.54%
AUM
$1.28T
AUM Growth
+$391B
Cap. Flow
+$19.1B
Cap. Flow %
1.49%
Top 10 Hldgs %
26.66%
Holding
15,023
New
1,956
Increased
5,793
Reduced
5,445
Closed
1,748
Avg Time Held Equity + Options
3.8 years
Top 10 Avg Time Held Equity + Options
5.1 years
Top 20 Avg Time Held Equity + Options
5.8 years
Avg Time Held Equity only
2.2 years
Top 10 Avg Time Held Equity only
1.8 years
Top 20 Avg Time Held Equity only
3.4 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 93.8%
2 Technology 2.93%
3 Communication Services 0.62%
4 Consumer Discretionary 0.61%
5 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
IXHL icon
12751
PUT
Incannex Healthcare
IXHL
$24.7M
$62K ﹤0.01%
+16,500
New +$60.3K
2026 Q2
0 quarters
RDI icon
12752
Reading International Class A
RDI
$43.3M
$62K ﹤0.01%
48,469
+18,204
+60% +$21K
2023 Q4
10 quarters
DAVA icon
12753
Endava
DAVA
$75M
$62K ﹤0.01%
21,907
-4,802
-18% -$17.7K
2026 Q1
1 quarter
HRZN icon
12754
PUT
Horizon Technology Finance
HRZN
$231M
$61.5K ﹤0.01%
+13,000
New +$56.2K
2026 Q2
0 quarters
ZNTL icon
12755
PUT
Zentalis Pharmaceuticals
ZNTL
$155M
$61.1K ﹤0.01%
12,600
-32,700
-72% -$131K
2026 Q1
1 quarter
SRTA icon
12756
Strata Critical Medical
SRTA
$474M
$60.7K ﹤0.01%
11,510
-15,151
-57% -$79.7K
2021 Q1
21 quarters
NAKA icon
12757
Nakamoto
NAKA
$82.7M
$60.6K ﹤0.01%
15,352
+7,689
+100% +$51.3K
2025 Q3
3 quarters
NRDY icon
12758
CALL
Nerdy
NRDY
$45.6M
$60.5K ﹤0.01%
4,387
-4,873
-53% -$63.7K
2024 Q4
6 quarters
CCC icon
12759
CALL
CCC Intelligent Solutions
CCC
$4.55B
$60.4K ﹤0.01%
11,700
-6,300
-35% -$31.2K
2026 Q1
1 quarter
ABEV icon
12760
Ambev
ABEV
$41.6B
$60.4K ﹤0.01%
19,223
-156,896
-89% -$491K
2023 Q4
10 quarters
EEX icon
12761
PUT
DELISTED
Emerald Holding
EEX
$60K ﹤0.01%
+11,900
New +$57.8K
2026 Q2
0 quarters
NNOX icon
12762
PUT
Nano X Imaging
NNOX
$24.7M
$59.9K ﹤0.01%
51,600
+27,500
+114% +$51.8K
2020 Q3
23 quarters
DKI icon
12763
DarkIris
DKI
$74.3K
$59.7K ﹤0.01%
+246
New +$78.3K
2026 Q2
0 quarters
CVRX icon
12764
CVRx
CVRX
$17M
$59.6K ﹤0.01%
11,593
-4,851
-30% -$31.3K
2023 Q4
10 quarters
SUIG icon
12765
Sui Group Holdings
SUIG
$57.7M
$59.6K ﹤0.01%
51,358
+25,320
+97% +$36.5K
2025 Q2
4 quarters
SIGA icon
12766
CALL
SIGA Technologies
SIGA
$208M
$59K ﹤0.01%
+16,200
New +$72.5K
2026 Q2
0 quarters
LTRN icon
12767
Lantern Pharma
LTRN
$5.84M
$58.7K ﹤0.01%
+14,073
New +$41.3K
2026 Q2
0 quarters
GANX icon
12768
CALL
Gain Therapeutics
GANX
$42.7M
$58.7K ﹤0.01%
28,900
-9,400
-25% -$17.3K
2025 Q4
2 quarters
HRTX icon
12769
Heron Therapeutics
HRTX
$57.3M
$58.5K ﹤0.01%
137,067
-151,186
-52% -$121K
2017 Q2
36 quarters
TVGNW icon
12770
Tevogen Warrant
TVGNW
$500K
$58.5K ﹤0.01%
1,027,391
+637,174
+163% +$26.2K
2025 Q4
2 quarters
MIND icon
12771
MIND Technology
MIND
$26.7M
$58.3K ﹤0.01%
+12,355
New +$80.9K
2026 Q2
0 quarters
OPAD icon
12772
PUT
Offerpad Solutions
OPAD
$9.15M
$58.3K ﹤0.01%
11,800
+9,190
+352% +$61.5K
2025 Q3
3 quarters
LZM icon
12773
CALL
Lifezone Metals
LZM
$373M
$58.2K ﹤0.01%
+15,000
New +$70.1K
2026 Q2
0 quarters
GSRFR icon
12774
GSR IV Acquisition Corp Rights
GSRFR
$58K ﹤0.01%
25,201
+12,864
+104% +$30K
2026 Q1
1 quarter
KLRS icon
12775
Kalaris Therapeutics
KLRS
$34.3M
$57.9K ﹤0.01%
14,221
-38,463
-73% -$200K
2025 Q4
2 quarters

Similar funds

Jeff Yass's Q2 2026 Portfolio in Review

As of Q2 2026, Jeff Yass held 15,023 positions worth $1.28T, up 44% from $893B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Jeff Yass's Q2 2026 filing shows 1,956 new, 5,793 increased, 5,445 reduced and 1,748 closed positions. Its largest new stake was Vanguard Total International Bond ETF: 5,720,864 shares worth $277M. The largest sale was Invesco QQQ Trust, an estimated $1.78B.

By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

  • Jeff Yass's largest Q2 2026 buy was Vanguard Total International Bond ETF: 5,720,864 shares worth $277M.
  • Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $2.87B increase.
  • Jeff Yass's biggest Q2 2026 reduction was Invesco QQQ Trust, cutting an estimated $1.78B.
  • Jeff Yass fully exited iShares MSCI Emerging Markets ex China ETF in Q2 2026, selling an estimated $142M.
  • Jeff Yass's ten largest holdings make up 27% of its $1.28T portfolio in Q2 2026.
  • Jeff Yass opened 1,956 new positions and closed 1,748 in Q2 2026.
  • Jeff Yass's portfolio value rose 44% quarter-over-quarter to $1.28T.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.